Cefuroxime
Active ingredient · 2 therapeutic classes
Sold as CEFTIN
- Drug class
- Second-Generation Cephalosporins
- Availability
- Prescription only
- Routes
- Oral, Intravenous, Intramuscular
- Markets covered
- 3
- Products on record
- 46
- FDA reports (12 mo)
- 798
Overview
Cefuroxime is an active pharmaceutical ingredient in the Second-Generation Cephalosporins group (J01DC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 32 | May 29, 2026 |
| CA Canada | Health Canada | 9 | October 21, 2025 |
| US United States | FDA | 5 | October 8, 2025 |
GBUnited Kingdom· MHRA
32 products
Uses
1). 4) • Prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological surgery (including caesarean section) In treatment and prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
How to take
CACanada· Health Canada
9 products
Uses
CEFUROXIME FOR INJECTION, USP (Cefuroxime for Injection) is indicated for:
Treatment Cefuroxime for Injection, USP may be indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: • Lower Respiratory Tract Infections: Pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae including ampicillin- resistant strains, Klebsiella species, Staphylococcus aureus including ampicillin-resistant (but not methicillin-resistant) strains, Streptococcus pyogenes, and Escherichia coli.
• Urinary Tract Infections: Caused by Escherichia coli, and Klebsiella species. • Soft Tissue Infections: Caused by Staphylococcus aureus, including ampicillin-resistant (but not methicillin-resistant) strains, Streptococcus pyogenes, Escherichia coli, and Klebsiella species.
• Meningitis: Caused by Staphylococcus aureus including ampicillin-resistant (but not methicillin-resistant) strains, Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis. • Gonorrhea: Caused by Neisseria gonorrhoeae including ampicillin-resistant strains.
USUnited States· FDA
5 products
Uses
INDICATIONS AND USAGE
, Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. , and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp.
Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis, and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains).
Gonorrhea:
Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase producing strains).
Drug interactions
Known interactions involving Cefuroxime. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 325. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL283950114 · revised October 20, 2022
- [2]Health Canada (DPD) · 02241638 · revised March 22, 2025
- [3]FDA DailyMed · 07170ee3-1a24-42… · revised December 5, 2020 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.